An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bicycle Therapeutics plc (NASDAQ: BCYC) will present results from its Phase I/II trial of BT8009 at the 2023 ASCO GU Cancers Symposium, taking place in San Francisco from February 16-18, 2023. The conference call, scheduled for February 14 at 8:00 a.m. ET, will feature Dr. Capucine Baldini and Dr. Daniel Petrylak discussing the data on BT8009, a BTC targeting Nectin-4. The poster presentation, under the title 'BT8009-100,' will occur on February 17. Bicycle Therapeutics specializes in innovative therapies, focusing on advanced malignancies.
Positive
None.
Negative
None.
- Company to Host Conference Call on February 14 at 8:00 a.m. ET -
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that monotherapy dose escalation results of the ongoing Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, being held February 16-18, 2023 in San Francisco, California. On Tuesday, February 14, 2023 at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucine Baldini (Medical Oncologist, Gustave Roussy) and Dr. Daniel Petrylak (Professor of Medicine and Genitourinary Oncology, Yale School of Medicine) to discuss the data being presented.
Poster Presentation Details
Title: BT8009-100: A Phase I/II Study of a Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression, Including Urothelial Cancer
Abstract #: 498
Presenter: Capucine Baldini, M.D., on behalf of the BT8009-100 investigators
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date/Time: Friday, February 17, 3:30 p.m. to 5:00 p.m.; 8:15 p.m. to 9:15 p.m. ET
Conference Call Details
Bicycle Therapeutics will host a conference call and webcast on Tuesday, February 14, 2023 at 8:00 a.m. ET to review the data being presented. To access the call, please dial (866) 652-5200 (domestic) or (412) 317-6060 (international) and provide the Conference ID 10174689. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com.
About Bicycle Therapeutics Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.
